GO
Loading...

Faber Report: Biogen Idec Buying Stake in MS Drug

Wednesday, 6 Feb 2013 | 9:42 AM ET

CNBC's David Faber reports Biogen Idec is buying Elan's stake in MS drug Tysabri for $3.25 billion plus royalties.